A Diet Low in Fermentable Oligo-, Di-, and Monosaccharides and Polyols Improves Quality of Life and Reduces Activity Impairment in Patients With Irritable Bowel Syndrome and Diarrhea

Clinical Gastroenterology and Hepatology

Volumn 15, Issue 12, 2017, Pages 1890-1899.e3

  Eswaran, Shanti ^a   Chey, William D ^a   Jackson, Kenya ^a   Pillai, Sivaram ^a   Chey, Samuel W ^a   Han Markey, Theresa ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Functional Disorder; Nutrition; Psychology; Treatment

Indexed keywords

DISACCHARIDE; MONOSACCHARIDE; OLIGOSACCHARIDE; POLYOL; CARBOHYDRATE; POLYMER;

ADULT; AGE DISTRIBUTION; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIET SUPPLEMENTATION; DIETARY INTAKE; ETHNIC DIFFERENCE; FEMALE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL VALUE; PRODUCTIVITY; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; SLEEP QUALITY; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; COMPLICATION; DIET THERAPY; EXERCISE; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; AGED; ANXIETY; DEPRESSION; DIARRHEA; DIET THERAPY; EFFICIENCY; EXERCISE; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; POLYMERS; PROSPECTIVE STUDIES; QUALITY OF LIFE; SINGLE-BLIND METHOD; SUGARS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85028943188     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2017.06.044     Document Type: Article

References (46)

1. Drossman, D.A., Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology, 2016 Feb 19.
2. Power, A.M., Talley, N.J., Ford, A.C., Association between constipation and colorectal cancer: systematic review and meta-analysis of observational studies. Am J Gastroenterol 108 (2013), 894–903.
3. El-Serag, H.B., Olden, K., Bjorkman, D., Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 16 (2002), 1171–1185.
4. Gralnek, I.M., Hays, R.D., Kilbourne, A., et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119 (2000), 654–660.
5. Pare, P., Gray, J., Lam, S., et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther 28 (2006), 1726–1735 discussion 1710–1721.
6. Spiegel, B.M., The burden of IBS: looking at metrics. Curr Gastroenterol Rep 11 (2009), 265–269.
7. Hulisz, D., The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm 10 (2004), 299–309.
8. IBS in the real world survey, 2002, International Foundation for Functional Gastrointestinal Disorders, Milwaukee, WI.
9. Chang, L., Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 20:Suppl 7 (2004), 31–39.
10. Riedl, A., Schmidtmann, M., Stengel, A., et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. J Psychosom Res 64 (2008), 573–582.
11. Fond, G., Loundou, A., Hamdani, N., et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 264 (2014), 651–660.
12. Nojkov, B., Rubenstein, J.H., Chey, W.D., et al. The impact of rotating shift work on the prevalence of irritable bowel syndrome in nurses. Am J Gastroenterol 105 (2010), 842–847.
13. Patel, A., Hasak, S., Cassell, B., et al. Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 44 (2016), 246–258.
14. Van Oudenhove, L., Tornblom, H., Storsrud, S., et al. Depression and somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome. Gastroenterology 150 (2016), 866–874.
15. Grinsvall, C., Tornblom, H., Tack, J., et al. Psychological factors selectively upregulate rectal pain perception in hypersensitive patients with irritable bowel syndrome. Neurogastroenterol Motil 27 (2015), 1772–1782.
16. Van Oudenhove, L., Crowell, M.D., Drossman, D.A., et al. Biopsychosocial aspects of functional gastrointestinal disorders. Gastroenterology, 2016 Feb 18.
17. Simrén, M., Månsson, A., Langkilde, A.M., et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 63 (2001), 108–115.
18. Eswaran, S., Tack, J., Chey, W.D., Food: the forgotten factor in the irritable bowel syndrome. Gastroenterol Clin North Am 40 (2011), 141–162.
19. Barrett, J.S., Gearry, R.B., Muir, J.G., et al. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 31 (2010), 874–882.
20. Ong, D.K., Mitchell, S.B., Barrett, J.S., et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. J Gastroenterol Hepatol 25 (2010), 1366–1373.
21. Halmos, E.P., Power, V.A., Shepherd, S.J., et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 146 (2014), 67–75.e5.
22. Staudacher, H.M., Whelan, K., Irving, P.M., et al. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 24 (2011), 487–495.
23. Mazzawi, T., Hausken, T., Gundersen, D., et al. Effects of dietary guidance on the symptoms, quality of life and habitual dietary intake of patients with irritable bowel syndrome. Mol Med Rep 8 (2013), 845–852.
24. Eswaran, S.L., Chey, W.D., Han-Markey, T., et al. A randomized controlled trial comparing the low FODMAP diet vs modified NICE guidelines in US adults with IBS-D. Am J Gastroenterol 111 (2016), 1824–1832.
25. Bohn, L., Storsrud, S., Liljebo, T., et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology 149 (2015), 1399–1407.e2.
26. Drossman, D.A., The functional gastrointestinal disorders and the Rome III process. Gastroenterology 130 (2006), 1377–1390.
27. Spiegel, B.M., Gralnek, I.M., Bolus, R., et al. Clinical determinants of health-related quality of life in patients with irritable bowel syndrome. Arch Intern Med 164 (2004), 1773–1780.
28. Bellini, M., Gemignani, A., Gambaccini, D., et al. Evaluation of latent links between irritable bowel syndrome and sleep quality. World J Gastroenterol 17 (2011), 5089–5096.
29. Drossman, D., Morris, C.B., Hu, Y., et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 102 (2007), 1442–1453.
30. Peters, S.L., Yao, C.K., Philpott, H., et al. Randomised clinical trial: the efficacy of gut-directed hypnotherapy is similar to that of the low FODMAP diet for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 44 (2016), 447–459.
31. Pedersen, N., Andersen, N.N., Vegh, Z., et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 20 (2014), 16215–16226.
32. Hsiao, E.Y., McBride, S.W., Hsien, S., et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155 (2013), 1451–1463.
33. Bhat, M.I., Kapila, R., Dietary metabolites derived from gut microbiota: critical modulators of epigenetic changes in mammals. Nutr Rev 75 (2017), 374–389.
34. Cryan, J.F., Dinan, T.G., Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13 (2012), 701–712.
35. Ledochowski, M., Widner, B., Bair, H., et al. Fructose- and sorbitol-reduced diet improves mood and gastrointestinal disturbances in fructose malabsorbers. Scand J Gastroenterol 35 (2000), 1048–1052.
36. Collins, S.M., Bercik, P., The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 136 (2009), 2003–2014.
37. Buono, J.L., Tourkodimitris, S., Sarocco, P., et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits 7 (2014), 289–297.
38. Shepherd, S., Gibson, P.R., The complete low-FODMAP diet: a revolutionary plan for managing IBS and other digestive disorders. 2013, The Experiment, New York, NY.
39. Patrick, D.L., Drossman, D.A., Frederick, I.O., et al. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 43 (1998), 400–411.
40. Drossman, D., Morris, C.B., Hu, Y., et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 102 (2007), 1442–1453.
41. Drossman, D.A., Patrick, D.L., Whitehead, W.E., et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 95 (2000), 999–1007.
42. Zigmond, A.S., Snaith, R.P., The hospital anxiety and depression scale. Acta psychiatrica Scandinavica 67 (1983), 361–370.
43. Bjelland, I., Dahl, A.A., Haug, T.T., et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 52 (2002), 69–77.
44. Herrmann, C., International experiences with the Hospital Anxiety and Depression Scale–a review of validation data and clinical results. J Psychosom Res 42 (1997), 17–41.
45. Reilly, M.C., Bracco, A., Ricci, J.F., et al. The validity and accuracy of the Work Productivity and Activity Impairment questionnaire–irritable bowel syndrome version (WPAI: IBS). Aliment Pharmacol Ther 20 (2004), 459–467.
46. Spoormaker, V.I., Verbeek, I., van den Bout, J., et al. Initial validation of the SLEEP-50 questionnaire. Behavioral Sleep Med 3 (2005), 227–246.